Jury investor panel member

Aurelie Nowack | Principal at V-Bio Ventures

Aurelie Nowack is a Principal at V-Bio Ventures since 2022. Prior to joining V-Bio Ventures, Aurelie worked 10+ years at the intersection between industry and academia. She was responsible for Business Development at VIB, the Flemish Institute for Biotechnology for the centers of Microbiology and of Plant Systems Biology. Aurelie worked previously for BASF in innovation management and technology acquisition.

Aurelie has a scientific background, holding a PhD in Genetics from the Max Planck Institute of Plant Breeding Research and University of Cologne, Germany, an MSc in Biotechnology from Wageningen University in the Netherlands and a BSc in Biology from Imperial College, UK.

About V-Bio Ventures

V-Bio Ventures is a life science venture capital fund that co-creates startups and invests in early- to mid-stage companies with high growth potential. Our extensive network and expertise in the sector allow us to contribute more than just capital. We aim at being part of the DNA of the new ventures that we back.

We invest in private companies with differentiated technology addressing unmet needs. V-Bio helps transform scientific innovation into products that positively impact people’s lives. We look for innovative and transformational technologies with high societal and/or environmental impact potential. We focus on therapeutics, including both drug discovery and drug development.

We have a preferred relationship with the Belgium-based VIB, one of the world’s premier life science research institutes. Part of the companies we co-create are built on VIB-derived innovations. We additionally source deals coming from any research institute, entrepreneurial initiative, or spin-outs from mature companies, with a geographical focus on Europe.